UM-164, a Dual Inhibitor of c-Src and p38 MAPK, Suppresses Proliferation of Glioma by Reducing YAP Activity.

Cancers (Basel) · 2022 · PMC9658092 · PMID 36358761

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an obvious trendno p-value reported

As depicted in Figure 6 A,B, the mice treated with UM-164 showed an obvious trend of persistent atrophy compared with the control group, and the effect of the 10 mg/kg group was superior to that of the 5 mg/mL group.

also in 1,006 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.